Belgian radiopharmaceutical firm Ion Beam Applications (IBA) has completed development of a pencil-beam scanning (PBS) module for its proton beam therapy system.
The Louvain-la-Neuve company said it would be filing for U.S. Food and Drug Administration (FDA) clearance for the PBS module. When approved, PBS will be one of four treatment modes available on the company's IBA universal nozzle proton therapy product. The other modes include single scattering, double scattering, and uniform scattering.
Related Reading
IBA, NeuroSurvival Technologies partner, August 14, 2008
IBA, Lantheus ink radiopharma deal, July 31, 2008
IBA, Wilex ink licensing pact, June 6, 2008
IBA finalizes acquisition of CIS bio, May 30, 2008
IBA opens U.K. production center, March 14, 2008
Copyright © 2008 AuntMinnie.com
